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ABSTRACT 
 
A Streptozotocin-Induced Model of Alzheimer’s Disease in 
Mice with Wild-Type Human Tau 
 
Carolyn C. Rudy 
 
Alzheimer’s disease (AD) accounts for 60 to 80% of all dementias, affects over 5 million 
Americans, and incurs annual healthcare costs of over $200 billion (Alzheimer’s Association, 
2012).  Hyperphosphorylation of tau, the main component of neurofibrillary tangles observed in 
AD, leads to deficits in cell structure and function.  Because recent data suggest impairments in 
cerebral glucose utilization and energy metabolism play a prominent role in the pathogenesis of 
AD, we sought to create a mouse model that emulates the metabolic changes using 
intracerebroventricular infusions of streptozotocin (ICV-STZ) in transgenic mice expressing 
human tau.  The Barnes maze, a test of spatial learning and memory, and a panel of antibodies 
directed at biochemical changes in tau associated with AD were used to assess memory deficits 
and tau pathology, respectively.  The behavioral and biochemical findings of the current study 
provide inconsistent support for the use of an ICV-STZ model in mice expressing human tau, 
and future studies should employ a battery of behavioral assays to determine if subtle memory 
deficits occur. 
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A Streptozotocin-Induced Model of Alzheimer’s Disease in 
Mice with Wild-Type Human Tau 
Tauopathies are a group of neurodegenerative disorders involving the tau protein 
(Clavaguera et al., 2009).  Alzheimer’s disease (AD), the most common tauopathy, accounts for 
60 to 80% of all dementias and affects over 5 million Americans (Alzheimer’s Association, 
2012).  As the American public ages, the societal and economic costs are becoming increasingly 
burdensome: unpaid caregivers of AD patients worked over 17.4 billion hours in 2011, and AD-
related health care costs are expected to exceed $200 billion (Alzheimer’s Association, 2012).  In 
addition to memory loss, other early symptoms of AD include difficulties with problem solving, 
regulating one’s emotions, and completing familiar tasks (Alzheimer’s Association, 2012).  The 
disease progresses over the course of about 4 to 8 years during which cognitive functioning 
declines steadily until death (Alzheimer’s Association, 2012).  Pharmaceutical treatment of AD, 
which cannot halt or slow the progression of cognitive decline (Piau, Nourhashémi, Hein, 
Caillaud, & Vellas, 2011), is currently limited to two classes of drugs: uncompetitive N-methyl-
D-aspartate (NMDA) receptor antagonists and reversible acetylcholinesterase inhibitors. 
Tau, a microtubule-associated protein, is the main component of neurofibrillary tangles 
(NFTs) observed in AD and other neurodegenerative tauopathies (see Kolarova, García-Sierra, 
Bartos, Ricny, & Ripova, 2012 for review).  NFTs are primarily composed of 
hyperphosphorylated tau bound in paired helical filaments (Hong & Lee, 1997; Tokutake et al., 
2012).  In AD, NFTs form when tau aggregates in the somatodendritic part of the neuron 
(Hébert, Sergeant, & Buée, 2012), eventually resulting in neuronal death.  Plaques are a distinct 
hallmark of AD and are not found in any other tauopathies.  Plaques are composed primarily of 
beta-amyloid (Aβ), a 39 to 42 amino acid fragment derived from proteolytic processing of the 
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amyloid precursor protein (APP) (Haass et al., 1993; Ittner et al., 2010; Tokutake et al., 2012).  
Neuronal death, the third hallmark of AD, is most pronounced in areas of the brain related to 
executive functioning and memory, such as the frontal cortex (Lemmens et al., 2011; Sabuncu et 
al., 2011) and hippocampus (Sabuncu et al., 2011). 
Tau Plays a Significant Role in AD Etiology 
Increased production or decreased clearance of Aβ is believed to be the precipitating 
event in AD pathogenesis, a theory referred to as the amyloid cascade hypothesis (Hardy & 
Higgins, 1992).  However, several lines of evidence suggest that, although Aβ pathology may 
occur before tau pathology, it does not fully explain the cognitive decline observed in AD.  For 
example, NFT density is more closely correlated with disease severity than Aβ plaques (Berg et 
al., 1998; Kolarova et al., 2012).  Aβ plaques are frequently observed in older individuals with 
no cognitive dysfunctions; however, it is unusual to find tangles without the presence of AD or 
another related tauopathy (Piau et al., 2011).  Furthermore, tau pathology alone is capable of 
causing the neurodegeneration witnessed in sporadic and familial tauopathies (Sorrentino & 
Bonavita, 2007).  Further weakening support against the amyloid cascade hypothesis comes from 
clinical trials using drugs that lower Aβ levels.  Despite successfully lowering Aβ levels, the 
drugs do not decrease neuronal death or significantly improve cognitive functioning (Gervais et 
al., 2007; Gilman et al., 2005; Klafki, Staufenbiel, Kornhuber, & Wiltfang, 2006; Siemers, Dean, 
Demattos, & May, 2006).  For these reasons, the current proposal focuses on the role of tau in 
AD pathology.  
Tau is a microtubule-associated protein responsible for microtubule nucleation and 
stabilization in neurons (Eckermann et al., 2007).  In the human brain, there are a total of six 
isoforms of tau ranging from 352 to 441 amino acids long, with molecular weights between 45 
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and 65 kDa (Buée, Bussière, Buée-Scherrer, Delacourte, & Hof, 2000).  The different isoforms 
are created by alternative splicing of exons 2, 3, and 10 of the tau gene (Luk et al., 2012).  Exon 
10 is particularly important in tauopathies.  Inclusion of exon 10 results in the expression of four 
microtubule-binding repeat domains (4R), whereas the exclusion of exon 10 leads to only three 
microtubule-binding repeat domains (3R) (Kolarova et al., 2012).  Tauopathies often shift from 
an approximately 1:1 ratio of 3R to 4R in young, non-demented human brains to an excess of 4R 
tau in disease states, which is significant given the increased likelihood of 4R tau to dissociate 
from microtubules and aggregate (Adams, DeTure, McBride, Dickson, & Petrucelli, 2010).   
As a phosphoprotein, there are over 80 serine and threonine sites on tau that can be 
phosphorylated (Billingsley & Kincaid, 1997; Kolarova et al., 2012).  The abnormal 
phosphorylation of tau is a fundamental neuropathological event in AD (Kolarova et al., 2012). It 
is believed to be one of the earliest changes in the brain, with tau becoming more phosphorylated 
as the disease progresses (Crespo-Biel, Theunis, & Van Leuven, 2012).  The mechanisms by 
which tau becomes hyperphosphorylated are not fully understood, though a few have been 
identified.  Mechanisms that lead to exacerbated tau phosphorylation often involve increased 
kinase activity, or decreased phosphatase activity, leading to a decrease in the removal of 
phosphate groups from tau (see Iqbal & Grundke-Iqbal, 2008 for review).  Some of the kinases 
implicated include glycogen synthase kinase 3 beta (GSK3β) (Plattner, Angelo, & Giese, 2006), 
cyclin-dependent kinase 5 (Cdk5) (Ahlijanian et al., 2000; Plattner et al., 2006), and calcium- 
and calmodulin-dependent protein kinase-II (CaMKII; Bennecib, Gong, Grundke-Iqbal, & Iqbal, 
2001; Singh, Zaidi, Grundke-Iqbal, & Iqbal, 1996).  Both GSK3β and Cdk5 are proline-directed 
serine/threonine kinases responsible for phosphorylating tau at the sites most implicated in AD 
(Plattner et al., 2006).  Tau is also phosphorylated at two particular sites by CaMKII, which does 
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not belong to the same category of kinases as GSK3β and Cdk5 (Bennecib et al., 2001; Singh et 
al., 1996).  CaMKII does not phosphorylate tau at nearly as many sites as GSK3β and Cdk5 but 
contributes to further hyperphosphorylation (Cho & Johnson, 2003).  Similarly, down-regulation 
of phosphoseryl/phosphothreonyl protein phosphatase-2A (PP2A), which dephosphorylates tau 
at several sites, also contributes to phosphorylation of tau (Gong et al., 2000; Liu, Grundke-
Iqbal, Iqbal, & Gong, 2005; Wang, Grundke-Iqbal, & Iqbal, 2007).  PP2A activity, which is 
reduced in AD, further exacerbates the phosphorylation of tau caused by other proline-directed 
serine/threonine kinases (Liu & Wang, 2009; Qian et al., 2010).  Why the activity of kinases and 
phosphatases changes in AD is unclear, but research suggests metabolic abnormalities may play 
a role.  Early stages of AD are accompanied by metabolic abnormalities, such as a decrease in 
insulin levels in the brain (Frӧlich, Blum-Degen, Riederer, & Hoyer, 1999) and a drop in 
cerebral glucose utilization (Hoyer & Nitsch, 1989), resulting in alterations of these kinases in 
ways that promote tau phosphorylation (de la Monte, 2012).  PP2A is also implicated in 
negatively regulating the insulin signaling pathway (Mandavia & Sowers, 2012; Ugi et al., 
2004). 
Tau hyperphosphorylation can lead to various deficits in cell structure and function.  The 
hyperphosphorylation of tau prevents proper binding of microtubules, leading to decreased cell 
stability (Mongradón-Rodríguez et al., 2008) and axonal transport (Mandelkow, Stamer, Vogel, 
Thies, & Mandelkow, 2003).  In addition, tau hyperphosphorylation, and the subsequent 
unbinding of tau from microtubules, causes tau to mislocalize into the somatodendritic 
compartment (Gӧtz,  Chen, Barmettler, & Nitsch, 2000) and dendritic spines (Hoover et al., 
2010).  In vitro studies suggest that mislocalization of tau to dendritic spines, which is dependent 
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upon tau hyperphosphorylation, causes alterations in glutamatergic receptor trafficking, leading 
to long-term potentiation (LTP) deficits (Hoover et al., 2010) and presumably memory deficits.  
Although tau mutations have been linked to the pathogenesis of some tauopathies, 
including frontotemporal dementia (Goedert, Crowther, & Spillantini, 1998), Pick’s disease 
(Pickering-Brown et al., 2000), and progressive supranuclear palsy (Ezquerra et al., 1999), there 
are no reported tau mutations in AD.  To model tau pathology in AD, mutations linked to other 
tauopathies are often expressed in mice, and in some cases, the expression is restricted to brain 
regions involved in AD through the use of specific promoter systems (i.e., a region of DNA that 
initiates transcription of a particular gene).  For example, the rTg(TauP301L)4510 mouse (herein 
called TauP301L) expresses the proline-to-leucine mutation at the 301
st
 amino acid (P301L) in 
human tau associated with frontotemporal dementia and Parkinsonism linked to chromosome 17 
(FTDP-17) (Ramsden et al., 2005).  To create a more AD-like model, P301L human tau 
expression is driven by a forebrain-specific CaMKII promoter system, resulting in high levels of 
human tau expression in brain regions related to AD, including the hippocampus and neocortex 
(Ramsden et al., 2005).  TauP301L mice exhibit age-dependent tau hyperphosphorylation, NFTs, 
neuron loss, and memory impairment (Ramsden et al., 2005).  Although this model is incredibly 
useful and the phenotype closely parallels the tau-related changes observed in AD, identifying 
and characterizing the etiology of AD using such a model is not possible given that this tau 
mutation does not occur in AD.  
To Be Resolved 
Here, it was proposed to create a mouse model that closely mimics the precipitating 
events believed to underlie AD-related changes and to examine the resulting changes in tau 
pathology and memory.  Recent data have suggested that impairments in cerebral glucose 
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utilization and energy metabolism play an important role in the pathogenesis of AD.  The early 
stages of cognitive impairment in AD are accompanied, or even preceded, by decrements in 
glucose utilization and energy metabolism (de la Monte, 2012; Hoyer, 2004). Furthermore, 
insulin injections can improve cognitive functioning in individuals with AD (Craft et al., 1999; 
Watson & Craft, 2004).  To model the metabolic changes that take place in AD, 
intracerebroventricular (ICV) infusions of streptozotocin (STZ) were used.  ICV-STZ produces 
insulin-resistance in the brain, as well as a myriad of molecular and pathological features that 
mimic AD, including tau hyperphosphorylation (Grünblatt, Salkovic-Petrisic, Osmanovic, 
Riederer, & Hoyer, 2007).  To date, however, effects of ICV-STZ on tau pathology have only 
been examined in rodents that have rodent, not human, tau.  To determine effects of ICV-STZ on 
human tau, the rTg(TauWT)21221 mouse model (herein called TauWT), that expresses wild-
type human four-repeat (4R) tau, was used.  The TauWT mouse model does not exhibit memory 
deficits nor tau pathology (Hoover et al., 2010) but allowed us to foster a determination of effects 
of ICV-STZ on 4R human tau – a version of tau that is more prone to AD-related changes 
(Barghorn & Mandelkow, 2002) but does not lead to tau pathology on its own (Hoover et al., 
2010).  In a healthy brain, there is typically a 1:1 ratio of 3R to 4R tau, but in tauopathies, 
including AD, there is a shift to an excess of 4R (Liu & Gong, 2008).  Thus, the TauWT model 
allows an assessment of effects of ICV-STZ on a version of tau that is increased in AD and more 
prone to AD-related changes (Barghorn & Mandelkow, 2002).  Effects of ICV-STZ in TauWT 
mice were compared with control littermates expressing mouse tau, as well as with TauP301L 
mice, the most commonly used tau model of AD.  Whereas the pathology in ICV-STZ treated 
TauWT mice was not anticipated to be as severe as that in ICV-STZ treated TauP301L mice, it 
was expected to be more advanced than treated controls because of the presence of human 4R tau 
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in TauWT mice.  It was also predicted that memory deficits will correspond with levels of tau 
phosphorylation. 
Modeling AD Using Intracerebroventricular Streptozotocin Infusions 
Many models of AD use intracerebroventricular infusions of streptozotocin (ICV-STZ) to 
induce the following changes witnessed in human AD: an insulin resistant brain state, a 
decrement in brain glucose and energy metabolism, cognitive decline, cholinergic deficits, and 
oxidative stress.  Insulin is a vital hormone for carrying out day-to-day processes.  Problems with 
insulin in the brain, as witnessed in AD (Aviles-Olmos, Limousin, Lees, & Foltynie, 2013; 
Schubert et al., 2004) and induced by ICV-STZ (Grünblatt et al., 2007; Hoyer & Lannert, 2008; 
Salkovic-Petrisic & Hoyer, 2007), lead to a decrement in brain glucose and energy metabolism in 
which glucose cannot properly fuel cognitive functions.  This decline in cognitive functioning is 
a prominent feature of AD and can be replicated by an ICV-STZ model.  Glucose also plays a 
role in the regulation of acetylcholine (Loubatières-Mariani, Chapal, Alric, & Loubatières, 
1973), a neurotransmitter implicated in learning and memory (Hasselmo, 2006).  In AD and 
ICV-STZ models, acetylcholine levels are decreased compared to healthy controls (Blokland & 
Jolles, 1994; Bowen, Smith, White, & Davison, 1976; Davies & Maloney, 1976; Hellweg et al., 
1992; Perry, Perry, Blessed, & Tomlinson, 1977).  Lastly, oxidative stress, an imbalance between 
reactive oxygen species and chemicals that can break them down, is another damaging effect of 
AD emulated by an ICV-STZ model (Mao, 2013; Sharma & Gupta, 2001; Shoham, Bejar, 
Kovalev, & Weinstock, 2003).  The preceding changes are described in detail below. 
Insulin Resistant Brain State 
Insulin and insulin-like growth factors promote the uptake, oxidation, and storage of 
glucose (Bingham et al., 2002), a main energy source of the body.  Insulin receptors are 
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extensively expressed in the brain (Schubert et al., 2004) and have a high density in the 
hippocampus (Unger et al., 1989; Wickelgren, 1998) and cerebral cortex (Wickelgren, 1998), 
areas that are important for learning and memory and exhibit extensive AD pathology (Lalonde, 
Dumont, Staufenbiel, Sturchler-Pierrat, & Strazielle, 2002).  Insulin plays a role in modulating 
many cognitive functions including learning, memory, and synaptic plasticity (Zhao, Chen, 
Quon, & Alkon, 2004).   
In some disease states, the body can no longer appropriately respond to insulin.  The 
result, insulin resistance, prevents the body from accessing its stores of glucose.  In other words, 
the body loses its sensitivity to insulin, and insulin no longer effectively lowers blood glucose 
levels (Shanik et al., 2008).  Insulin resistance may impede the uptake of glucose as well as the 
ability of insulin to stimulate its receptors in the brain (Messier & Teutenberg, 2005). An insulin 
resistant brain state has since been implicated in the pathogenesis of both AD and Parkinson’s 
disease, another neurodegenerative disorder (Aviles-Olmos et al., 2013; Schubert et al., 2004).   
 In AD, there is a decrease in insulin levels in the brain (Frӧlich et al., 1999; Chen et al., 
2012).  Furthermore, insulin, insulin-like growth factor 1, and insulin-like growth factor 2 
receptor expression decline with the progression of AD (de la Monte & Wands, 2008).  That is, 
expression of these receptors decreases as the stage of pathology increases.  Insulin also plays a 
role in regulating the insulin signaling cascade, alterations of which can induce tau 
phosphorylation (Ho et al., 2004).  Normal or increased levels of cerebral insulin and insulin-like 
growth factor 1 down-regulate GSK-3β (Hong & Lee, 1997), a kinase that is responsible for 
phosphorylating tau (Plattner et al., 2006).  When this insulin signaling pathway is disturbed, 
higher levels of GSK-3β lead to greater tau phosphorylation (Connell et al., 2001).   
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ICV-STZ is an appropriate way to induce brain insulin system dysfunction as seen in AD 
(Grünblatt et al., 2007; Hoyer & Lannert, 2008; Salkovic-Petrisic & Hoyer, 2007).  Following 
ICV-STZ administration, there is a dramatic decrease in insulin receptor expression in the 
hippocampus along with a significant increase in tau phosphorylation (Grünblatt et al., 2007).  It 
is likely that this increase in tau phosphorylation is related to the over-activation of GSK-3β due 
to decreased phosphorylation at Ser9 (the serine at the ninth amino acid position) caused by the 
impaired insulin signaling pathway (Deng et al., 2009).  GSK-3β is a proline-directed 
serine/threonine kinase that readily phosphorylates tau at many of the phosphorylation sites 
implicated in AD (Plattner et al., 2006).  
Decrement in Brain Glucose/Energy Metabolism 
Glucose provides both the body and, in particular, the central nervous system with the 
biological energy needed to carry out its various functions (Sokoloff, 1980).  All bodily 
processes, including those in the central nervous system (Gibbs, Gibbs, Lennox, & Nims, 1942; 
Pardridge, 1983), are supported by the metabolism of glucose.  Glucose/energy metabolism in 
the brain is antagonistically controlled by insulin (Hoyer, 1996), so it is not surprising that 
decreases in insulin correspond with deficiencies in this system as well. 
The parietotemporal and frontal areas of the brain, which have high demands for glucose, 
as well as heightened sensitivities to insulin, develop early abnormalities in brain glucose/energy 
metabolism in AD (Correia et al., 2011; Henneberg & Hoyer, 1995; Hoyer, 2002; Hoyer, 2004).  
In early stages of AD, cerebral glucose utilization drops by 45% (Hoyer & Nitsch, 1989) and the 
production of adenosine triphosphate (ATP), a molecule used to transport chemical energy for 
metabolic processes, from glucose is cut in half (Mattson et al., 2001). 
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ICV-STZ administration results in long-term glucose/energy metabolism deficiencies 
(Hoyer, Henneberg, Knapp, Lannert, & Martin, 1996).  ICV-STZ, which has debilitating effects 
on brain glucose metabolism without perturbing basal blood glucose levels (Salkovic-Petrisic, 
Tribl, Schmidt, Hoyer, & Riederer, 2006), precipitates abnormalities in glucose/energy 
metabolism in numerous regions in the frontal, parietal, sensory, and entorhinal cortices (Duelli,  
Schröck, Kuschinsky, & Hoyer, 1994).  Following ICV-STZ in rats, reduced glucose utilization 
has been found in over a dozen brain areas, most notably in the frontal cortex and in all 
hippocampal subfields (Duelli et al., 1994).  Similar to what is witnessed in AD, there is a 
decrease in activity of glycolytic enzymes (chemicals which facilitate glycolysis) in the 
hippocampus (Plaschke & Hoyer, 1993).  In fact, glucose and glycogen metabolism falls by 10 to 
30% in rats receiving ICV-STZ (Plaschke & Hoyer, 1993).   
Cognitive Decline 
Progressive cognitive decline is a prominent feature of AD (Albert et al., 2011).  Memory 
deficits, including those in working (Miller, 1971; Morris, 1984; Kopelman, 1985) and semantic 
(Chertkow & Bub, 1990; Martin & Fedio, 1983; Weingartner, Grafman, Boutelle, Kaye, & 
Martin, 1983) memory types, comprise the most characteristic consequence of AD (Sjӧgren, 
Sjӧgren, & Lindgren, 1952).  Individuals with AD perform poorly on tests of semantic memory, 
such as picture naming or word finding, and these memory deficits become more profound as 
AD progresses (Hodges, Patterson, Oxbury & Funnell, 1992).  Patients with AD are also known 
to get lost in familiar surroundings, partially impacted by visuospatial disorientation (Henderson, 
Mack, & Williams, 1989). 
ICV-STZ results in progressive declines in cognitive functioning resembling those 
observed in AD (Grünblatt et al., 2007; Salkovic-Petrisic & Hoyer, 2007).  Rats that receive 
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ICV-STZ show deficits in learning and memory (Hoyer & Lannert, 1999; Lannert & Hoyer, 
1998).  In particular, ICV-STZ causes impairments in working and reference memory (Lannert 
& Hoyer, 1998), passive avoidance learning (Mayer, Nitsch, & Hoyer, 1990), and spatial 
discrimination (Blokland & Jolles, 1993; Blokland & Jolles, 1994). 
Cholinergic Deficits 
In addition to abnormal cerebral glucose utilization and energy metabolism, various 
neurotransmitter systems have been implicated in the progression of AD.  Synthesis of 
acetylcholine, an important neurotransmitter for learning and memory (Hasselmo, 2006), 
decreases in the AD brain (Sims et al., 1980).  Early stages of AD are accompanied by the 
degeneration of cholinergic nuclei in the basal forebrain as well as their projections in nearly all 
cortical areas (Whitehouse, Price, Clark, Coyle, & DeLong, 1981).  The degeneration of 
cholinergic neurons leading to instabilities in serotoninergic, noradrenergic, and dopaminergic 
systems is correlated with the progression of cognitive decline in AD (Baskin et al., 1999; Wang 
et al., 2007).  Analysis of postmortem brain samples of AD patients has found a significant 
decrease in cholinergic neurons (Bowen et al., 1976; Davies & Maloney, 1976; Perry et al., 
1977).  It is also worth noting that one of the key components of acetylcholine, acetyl-CoA, is 
controlled by glucose/energy metabolism (Gibson, Jope, & Blass, 1975).  Because there is a 
decrement in glucose/energy metabolism in AD, corresponding reductions in acetyl-CoA may 
explain the vulnerability in the cholinergic system (Wurtman, 1992). 
ICV-STZ causes cholinergic system dysfunctions (Blokland & Jolles, 1994; Hellweg et 
al., 1992).  One week after ICV-STZ administration, activity of choline acetyltransferase, an 
enzyme needed to synthesize acetylcholine, is reduced in the hippocampus (Blokland & Jolles, 
1994; Hellweg et al., 1992).  ICV-STZ also increases activity of the enzyme that breaks down 
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acetylcholine, acetylcholinesterase (Agrawal, Tyagi, Shukla, & Nath, 2009; de la Monte, Tong, 
Lester-Coll, Plater, & Wands, 2006), further exacerbating its reduced presence in the brain.  
Interestingly, the reduced presence of choline acetyltransferase in the hippocampus is correlated 
with impaired spatial discrimination ability as measured in the MWM (Blokland & Jolles, 1994).   
Oxidative Stress 
New evidence suggests that oxidative stress may occur before the earliest symptoms of 
AD (Mao, 2013).  The brain is disproportionately susceptible to oxidative stress because of its 
high oxygen consumption and lipid content coupled with relative scarcity of antioxidant enzymes 
(Coyle & Puttfarcken, 1993).  Cerebral mitochondria, the organelles in cells that are mainly 
responsible for generating energy-rich ATP, are structurally damaged in the brains of individuals 
with AD (Hirai et al., 2001).  Damage to the mitochondria results in the release of free radicals, 
which are implicated in causing oxidative stress (Smith et al., 1996). Oxidative stress has been 
associated with several neurodegenerative disorders, including Parkinson’s disease, amyotrophic 
lateral sclerosis (ALS), and AD (Markesbery, 1997).   
In an ICV-STZ model, oxidative stress precedes memory deficits (Sharma & Gupta, 
2001; Shoham, Bejar, Kovalev, Schorer-Apelbaum, & Weinstock, 2007).  Alkylating properties 
of STZ produce reactive oxygen species that eventually lead to neurodegeneration and DNA 
damage (Lester-Coll et al., 2006).  An increase in free radicals combined with a decrease in 
glutathione, an important antioxidant responsible for reacting with free radicals, correlates with 
greater levels of oxidative stress in an ICV-STZ model of AD (Sharma & Gupta, 2001).  Lipid 
peroxidation, a gauge of free radical production, also increases in this model (Sharma & Gupta, 
2001). 
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Together, these studies suggest that an ICV-STZ model is an ecologically valid method to 
induce the biochemical and behavioral effects seen in AD. 
Testing of Spatial Memory Using the Barnes Maze 
 In AD, some of the earliest changes in tau pathology affect the hippocampus, a brain 
region important in learning and memory (Altman & Das, 1965; Kaplan & Hinds, 1977).  
Because AD has profound effects on the hippocampus (Arriagada, Growdon, Hedley-Whyte, & 
Hyman, 1992; Hof et al., 1992; Morris & Fulling, 1988), it is important to use a test that is 
sensitive to alterations in hippocampal-dependent memory.  In order to assess effects of ICV-
STZ administration on the hippocampus, hippocampal-dependent memory test was administered.  
Although there are several different tests widely used to evaluate hippocampal-based learning 
and memory in animal models, the Barnes maze is best suited for this study given the ability to 
test the brain region of most interest with fewer disadvantages than other comparable 
assessments. The rationale for using the Barnes maze, as opposed to other hippocampal-
dependent memory tests, is discussed below. 
There are four commonly used hippocampal-dependent memory tests: the Morris water 
maze (MWM; Gerlai, 2001), fear conditioning (Burman & Gewirtz, 2007; Gerlai, 2001), radial 
arm maze, and Barnes maze (Barnes, 1979).  In the MWM, mice must locate a hidden platform 
in a large tank of water (Morris, 1984).  The mice use distal cues to learn the spatial location of 
the escape platform.  The accurate directionality of swimming paths in the MWM, despite the 
hidden platform, indicates that spatial learning is indeed assessed (Morris, 1984).  The contextual 
fear conditioning task and trace fear conditioning task, other tests of hippocampal-dependent 
learning and memory (Burman & Gewirtz, 2007; Gerlai, 2001), use cue recognition (contextual) 
or temporal discrimination (trace) to predict the presence of a shock.  The radial arm maze 
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involves placing food at the ends of the arms of a maze and having a food-restricted animal find 
the food as efficiently as possible given the extra-maze cues (Meck, Church, & Olton, 1984).  
Re-visiting arms where the food has already been eaten indicates a dysfunction in spatial 
memory.  Lastly, the Barnes maze is a large circular platform with many holes around the 
perimeter in a brightly-lit room.  One of the holes allows the mice to exit the maze and hide in a 
dark box, relying on a tendency for mice to choose dark, enclosed spaces over open, brightly lit 
ones (Harrison, Reiserer, Tomarken, & McDonald, 2006).  Mice can utilize extra-maze cues to 
locate the escape box as quickly as possible.  Induced hippocampal lesions correlating with 
hindered performance on the MWM (Logue, Paylor, & Wehner, 1997) and fear conditioning task 
(Logue et al., 1997) confirm their validity as measures of hippocampal-dependent memory, and 
the preceding analogous tests have been developed using the same reliance on spatial learning 
and memory.  Although all of the preceding tests assess spatial learning and memory, different 
motivational factors, motor behaviors, and environmental conditions differentiate them (Gerlai & 
Clayton, 1999).   
Of these four different tests of hippocampal-dependent learning and memory, the MWM 
is the most widely used (Vorhees & Williams, 2006).  Through extensive testing in the past few 
decades, the ability of the MWM to assess hippocampal-dependent spatial navigation and 
reference memory has been confirmed (Vorhees & Williams, 2006).  It is also relatively 
impervious to species and strain differences, and reliable despite variances in tank configurations 
and testing procedures (Vorhees & Williams, 2006).  The MWM also has its own share of 
disadvantages.  Repeatedly removing the mice from the water tank results in slight hypothermia. 
Because hypothermia causes tau phosphorylation (Planel et al., 2004; Planel et al., 2007), the 
practicality of using this test with tau mice is limited.  Furthermore, the MWM (Dudchenko, 
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Goodridge, Seiterle, & Taube, 1997) employs an aversive stimulus. The stress induced by these 
tests may result in unintentional tau phosphorylation because kinases that phosphorylate tau are 
activated by stress (Goedert et al., 1997).   
Contextual and trace fear conditioning tasks are other valuable measures of hippocampal-
dependent memory.  Like the MWM, these tests do not require extensive pre-training and can be 
used as a test of both nonspatial and spatial learning (McEchron, Bouwmeester, Tseng, Weiss, & 
Disterhoft, 1998).  However, fear conditioning tasks also use an aversive stimulus (Phillips & 
LeDoux, 1992), resulting in an increase of stress-related hormones (Daviu, Delgado-Morales, 
Nadal, & Armario, 2012). 
The radial arm maze is beneficial in that it does not employ an aversive stimulus; rather, 
food is used as a reinforcer (Hodges, 1996).  However, using food as a reinforcer is a possible 
confounding variable between the ICV-STZ and control mice.  Following ICV-STZ infusion, the 
threshold for lateral hypothalamic self-stimulation is lowered, suggesting that reward circuitry in 
the brain is sensitized to electrical impulses (Carr, Kim, & Cabeza de Vaca, 2000).  Given that 
food is another stimulus known to activate the brain’s reward pathway (Lobo, 2012), it was 
possible that the ICV-STZ mice would differentially respond for food compared to the control 
mice.  Also, in order for food to effectively serve as a reinforcer, the mice must have restricted 
diets or be maintained below their free-feeding weight, which is potentially dangerous for mice 
with insulin and glucose metabolism deficiencies.  There is additional evidence that suggests that 
hypoglycemia-induced binge feedings may affect body composition (McNay et al., 2012). 
The Barnes maze is particularly useful because it does not use a food as a reinforcer.  
Because implementing a test with a food reinforcer is not feasible for the reasons mentioned 
above, it is necessary to select a test that relies on a different kind of reinforcer.  Although the 
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fan used in the Barnes maze is aversive, the stress it induces is negligible compared that of the 
MWM or fear conditioning task. For example, the MWM results in greater increases in plasma 
corticosterone, a biological indicator of stress, than the Barnes maze (Harrison, Hosseini, & 
McDonald, 2009). A potential downfall of the Barnes maze is its sensitivity to strain differences.  
For instance, different mouse strains have been shown to react differently to the presence of 
various stimuli (Youn et al., 2012).  It is possible that particular genetic factors of the strains 
used in this experiment would result in the mice spending more or less time to escape the fans 
and lights, and thus invalidating the measures used to test memory (Nguyen, Abel, Kandel, & 
Bourtchouladze, 2000).  For the purpose of this experiment, the advantages of the Barnes maze 
outweigh its disadvantages.  Neither the TauP301L nor TauWT lines have been previously 
evaluated in the Barnes maze.  However, previous studies suggest PS19 mice, which overexpress 
human tau (1N4R) containing the P301S mutation found in FTDP-17, exhibit deficits in spatial 
learning and memory as assessed by the Barnes maze (Brunden et al., 2010).  Given the 
particular limitations of the MWM, fear conditioning task, and radial arm maze for this model, 
the Barnes maze was implemented in this study.  The unique combination of advantages and 
disadvantages present in the Barnes maze made it best-suited for the unique challenges of this 
particular experiment given that the Barnes maze minimizes corticosterone spikes (Harrison et 
al., 2009), food deprivation, and hypothermia. 
Statement of the Problem 
Alzheimer’s disease (AD) is a common neurodegenerative disorder affecting millions of 
people with no known cause or cure.  It is characterized by the presence Aβ plaques and NFTs 
composed primarily of tau, a microtubule-binding protein (Kolarova et al., 2012).  Late-stage 
AD ends with profound neuronal loss.  To date, most research has focused on the role of Aβ in 
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initiating the disorder; however, clinical trials using Aβ-modifying drugs have failed to slow or 
halt the progression of the disease, despite successfully decreasing Aβ levels (Small & Duff, 
2008).  Thus, it is necessary to investigate other potential etiologies, including abnormalities in 
the tau protein. 
Tau, a protein in the brain responsible for microtubule nucleation and stabilization 
(Eckermann et al., 2007), aggregates into the pathological NFTs seen in AD.  Tau pathology 
alone is capable of causing the neurodegeneration found in sporadic and familial tauopathies 
(Sorrentino & Bonavita, 2007), and the aberrant phosphorylation of tau is an essential 
neuropathological event in AD (Kolarova et al., 2012).  The mechanisms by which tau is 
hyperphosphorylated are not fully understood, but numerous metabolic abnormalities, such as a 
decrease in insulin levels in the brain (Frӧlich et al., 1999) and a drop in cerebral glucose 
utilization (Hoyer & Nitsch, 1989), are present in AD and result in tau phosphorylation (de la 
Monte, 2012).   
Recent advancements made in AD mouse models allow for the pathological role of tau to 
be better evaluated.  Mice expressing mutant human tau, referred to as TauP301L, have a 
transgene with a proline-to-leucine mutation at the 301
st
 amino acid found in frontotemporal 
dementia with parkinsonism-17 (FTDP-17), another tauopathy (Orr, Pitstick, Canine, Ashe, & 
Carlson, 2012).  Although the mutation is found in FTDP-17, TauP301L mice are generally 
considered a mouse model of AD because (1) use of a CaMKII promoter restricts pathology to 
brain regions implicated in AD (i.e., the forebrain) and (2) the mutation, when restricted to the 
forebrain, results in formation of NFTs, neuronal death, and progressive memory loss as 
observed in AD (Ramsden et al., 2005).  Finally, TauWT mice are another valuable mouse 
model because they express the 4R version of human (rather than rodent) tau without a genetic 
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mutation.  These mice allow for the manipulation of variables that may precipitate AD and 
subsequent evaluation of tau pathology.  TauWT mice can also serve as controls for the 
overexpression of human tau in mice to yield support for the assumption that any memory 
deficits or pathological changes are attributable to alterations in tau (e.g., tau 
hyperphosphorylation) and not the overexpression of human tau per se.  
ICV-STZ was administered to both the TauP301L and TauWT mice, as well as littermate 
controls, to emulate the early metabolic changes found in the AD brain. By doing so, it was 
anticipated that a more ecologically valid mouse model of AD would be developed using the 
TauWT mice that does not rely on genetic mutations.   
Method 
Subjects and Treatments 
In total, 56 male mice were used (Figure 1A).  These mice had unrestricted access to food 
and water and were group housed in a temperature- and humidity-controlled colony room with a 
12-hour light/dark cycle. 
The generation of TauWT and TauP301L mice has been described extensively in the past 
(Hoover et al., 2010; Ramsden et al., 2005; SantaCruz et al., 2005).  Briefly, mice expressing 
mutant human four-repeat tau lacking the N-terminal sequences (4R0N), referred to as 
TauP301L, were created by crossing responder and activator lines.  Responder mice on the 
FVB/N background, heterozygous for the Tetracycline Response Element (TRE)-TauP301L 
transgene, are bred with activator mice on the 129S6 background, heterozygous for the tet-off 
tetracycline transactivator (tTa) reading frame downstream of a Ca
2+
-calmodulin (CaMKII) 
promoter element (SantaCruz et al., 2005).  The breeding of heterozygous responder and 
activator mice produces four genotypes with the following nomenclature, TauP301L/CKtTA, 
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and encompasses what is referred to as the TauP01L mice (+/+) and Controls (-/+, +/-, -/-).  To 
limit the variability introduced by tTa expression, only activator positive mice (-/+) were used as 
controls.  No behavioral differences exist between the three control groups, and human tau is not 
expressed (Hoover et al., 2010; Ramsden et al., 2005; Santacruz et al., 2005).  TauWT mice were 
produced in the same manner, with the exception that TauWT mice express 4R0N human tau 
without the P301L mutation. 
In TauP301L and TauWT mice, the expression of human tau is limited to the forebrain 
with a CaMKII promoter and controlled through the use of a tetracycline transactivator (tTa) 
protein (Ramsden et al., 2005).  TauP301L mice have a proline-to-leucine mutation at the 301
st
 
amino acid found in frontotemporal dementia with parkinsonism-17 (FTDP-17), another 
tauopathy (Orr, Pitstick, Canine, Ashe, & Carlson, 2012).  Although the mutation is found in 
FTDP-17, the pathology in TauP301L mice is restricted to areas of the brain that are affected by 
AD (i.e., the forebrain) by the CaMKII promoter.  The mutation, when restricted to the forebrain, 
results in formation of NFTs, neuronal death, and progressive memory loss as observed in AD 
(Ramsden et al., 2005).  Approximately half of the controls were (-/+) littermates of the TauWT 
mice and half were (-/+) littermates of the TauP301L mice.  To control for differences in 
transgene copy number, which can affect transgene expression (Kong et al., 2009), no more than 
two mice of the same transgene [Tg; i.e., (-/+) or (+/+)] from one litter were assigned to the same 
treatment condition. 
 The tet-off system allowed for regulatable expression of tau protein with the use 
doxycycline (Figure 1B).  In the tet-off system, the presence of doxycycline prevents the 
transcription of tau by preferentially binding to the TRE.  In the absence of doxycycline, 
transcription occurs when the tTa protein binds to the TRE.  During conception until 2 months of 
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age, the mice received water with 40 parts per million (ppm) doxycycline hyclate to suppress tau 
expression during development (Figure 2C; Liu, Wang, Brenner, Paton, & Kasparov, 2008).  
Dams were placed on doxycycline water 2 weeks prior to breeding, and experimental offspring 
continued doxycycline until they were approximately 2.5 months of age. On the day of the 
surgery, doxycycline water was replaced with regular water and transcription of tau was allowed 
to occur for approximately 3.5 months (SantaCruz et al., 2005).  All experimental procedures 
were approved by the West Virginia University Animal Care and Use Committee. 
Surgery and ICV-STZ Administration  
On the same day mice were removed from doxycycline, mice received either a single, 
bilateral infusion of ICV-STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose); 3 
mg/kg; 2.5 µl/side) dissolved in 0.05 M citrate vehicle (pH 4.5) or vehicle (citrate buffer) into the 
lateral ventricles.  Sterile conditions were maintained during surgeries.  After induction with 5% 
isoflurane for 3 min, the mice were injected subcutaneously with 1 mg/kg ketoprofen, 1mg/kg 
bupivacaine, and 3 mg/kg sterile saline.  The fur in the surgical site was clipped and shaved, the 
area was cleaned with alternating 70% isopropyl and iodine, and a 2 cm longitudinal incision 
was made at the skull midline.  The infusions were performed while the mice were anesthetized 
with 2-4% isoflurane and placed into a stereotaxic device.  Coordinates of the infusions, based 
off of bregma, were ±1.0 mm lateral, -0.5 mm posterior, and -2.5mm ventral (Coomans, De 
Rydt, & Van Proeyen, 2011).  To facilitate the flow of the infusion into the brain, the syringe 
was slowly pulled up through the ICV from -2.5mm to -2.2mm.  Microinfusion of STZ or 
vehicle was controlled by a GenieTouch Syringe Pump (Kent Scientific, Connecticut, USA).  
Twenty-eight gauge injectors were attached to 25 µl Hamilton syringes to deliver STZ or vehicle 
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at a steady rate of 1 µl/min for 2.50 min per side with an additional 5 min for diffusion.  The 
holes in the skull were filled in with bone wax and the incision was closed with surgical glue. 
Immediately following surgery, the mice were removed from anesthesia, placed into a 
cage half-covered with a heating pad, and examined closely for appropriate respiration patterns 
and the return of reflexes. The mice remained alone in this post-operative cage for 30 min.  For 
at least one hour after surgery, the mice were monitored for signs of distress and the ability to 
ambulate before being returned to the colony in cages with no more than three mice.  On post-
operative days 1, 2, and 3, 3 mg/kg sterile saline and 1 mg/kg ketoprofen were injected 
intraperitoneally and subcutaneously, respectively, to alleviate discomfort.  Mice also received 
moist chow during this period.  After post-operative day 3, the mice were allowed to return to 
their original cage.  
Barnes Maze  
 At approximately 5.5 months of age (Figure 1C), the mice began the first of two 
habituation days for behavioral testing, which immediately preceded the five acquisition days 
and two probe trials. 
Apparatus.  The Barnes maze is a large, flat, white platform (diameter=122 cm) with 
forty holes (diameter=5 cm) equally spaced around the perimeter.  The platform was raised 
approximately 108 cm above the ground.  Between every trial, the maze was cleaned with a 35% 
ethanol solution.  A Logitech HD Pro Webcam C920 (Romanel-sur-Morges, Switzerland) 
camera mounted above the platform recorded all trials using Logitech Webcam software.  
Recorded trials were later viewed by a blinded experimenter, and slowed-down or repeated as 
necessary, to assess for the variables of interest. 
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Habituation.  For the two days preceding acquisition trials, the mice were habituated to 
the maze.  In this stage, the spatial cues around the room were not present, the fans were turned 
off, and the room light was turned on.  On Day 1 of habituation, the mice were placed on the 
platform next to its respective escape hole under a transparent, plastic breaker.  The mice were 
able to explore the escape box and the area immediately surrounding it, but were not able to 
access the rest of the maze.  This allowed the mice to learn how to access the escape box 
underneath the platform.  After 5 min, the mice were returned to its home cage.  The mice were 
each subjected to two trials of this procedure with about 25 min between trials.  On Day 2 of 
habituation, the mice began in the center of the platform under a transparent, plastic beaker.  
After 10 s, the beaker was raised and the mice were gently guided to the escape box in the target 
hole.  Once the mice entered the box, the hole was covered for 2 min.  After the 2 min had 
elapsed, the mice were returned to its home cage.  The two stages of habituation ensured that the 
mice learned how to access the escape hole, and that the escape hole could be found from the 
center of the platform to escape from the aversive stimuli.  The mice each completed two trials 
on habituation Day 2 and there was approximately 25 min between trials. 
Acquisition.  The acquisition phase took place on Days 3 through 7.  Under one hole, a 
small, dark recessed chamber, referred to as the escape box, was attached to the bottom of the 
platform.  The escape box was accessible by entering the target hole.  The room light was turned 
on straight above the maze, fans were directed at the platform from four sides, and spatial cues 
were placed around the room.   The escape box was placed in the same hole for each trial relative 
to extra-maze spatial cues placed on the walls of the room.  Although the maze was cleaned with 
ethanol between each trial, it was also rotated around its central axis to control for possible 
remaining odor cues.  After rotation, the escape box was realigned with the extra-maze cues.  
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The mice began the trial under a transparent, plastic beaker in the center of the platform.  After 
10 s, the beaker was raised and the mice were free to find the escape box.  The trials ended 30 s 
after the mice entered the escape box.  If the mice did not enter the escape box during the 3 min 
trial, the experimenter gently guided the mice into it and covered the hole for 30 s.  The mice 
were each subjected to three trials on each day with approximately 20 min between trials.   
The following variables were assessed during the acquisition trials: hole deviation, total 
errors, total latency, primary errors, primary latency, and search strategy.  For each of these 
variables, an encounter with a hole was defined as the mice sticking their entire heads into the 
hole.  The hole deviation was measured by determining how many holes were between the target 
hole and first hole the mice encountered on the platform.  Total errors included the number of 
holes the mice encountered before entering the escape box, and total latency included the total 
time before the mice entered the escape box.  Total errors and latency may be confounded by the 
tendency of some mice to explore the maze even after initially locating the hole (Harrison et al., 
2006).  With this in mind, primary errors and primary latency were also used.  Primary errors 
included the number of holes that the mice encountered before dipping its head into the target 
hole and primary latency was the time lapse between the beginning of the trial and the first 
encounter with the target hole.  Lastly, there were three different search styles: random, serial, 
and spatial.  Random was a nonsystematic searching strategy characterized by multiple crossings 
through the center of the platform or inability to find the target hole.  A serial search strategy 
involved encounters with three consecutive holes around the edge of the platform.  Finally, a 
spatial search strategy was used when mice rely on extra-maze cues to navigate directly within 
two holes of the target hole.  
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Probe.  The first of two probe trials took place 24 h after the last acquisition trial.  The 
second probe trial was one week following the first.  The escape box was removed for the probe 
trials.  The mice were placed into a transparent, plastic beaker at the center of the platform.  
After 10 s, the beaker was removed and the mice were free to search the maze.  In addition to 
total session time (90 s), three 30 s bins were also evaluated Probe trials lasted 90 s with three 
bins: 0-30 s, 31-60 s, and 61-90 s.  It was expected that the response of head pokes into the target 
hole would begin to be extinguished in the 31-60 s and 61-90 s bins as the mice search for the 
box without being able to locate the correct hole.  The variables measured during the probe trials 
included the time spent to reach the target hole where the escape box was previously hidden, the 
number of encounters with the target hole per bin, and the number of encounters with each error 
hole per bin.   
Glucose Testing 
 One day after the last probe trial of Barnes maze testing, fasting blood glucose readings 
were obtained from the mice to ensure no peripheral effects of ICV-STZ treatment.  All food was 
removed from the cages in the morning, and 5.5 hours later, testing took place.  To obtain a 
blood sample, the mice were first restrained in a 50 ml conical vial with drilled air holes, and the 
upper thighs of the mice were shaved with electric clippers and cleaned with 70% alcohol.  A 27-
gauge needle was used to puncture the saphenous vein, and a TRUEresult Blood Glucose 
Monitoring System with TRUEtest Blood Glucose Test Strips (Nipro Diagnostics, Osaka, Japan) 
was used to provide a reading. 
Antibodies 
To assess progression of tau pathology, antibodies with differential abilities to detect 
stage-specific, biochemical changes in tau were used after the mice had been euthanized (Table 
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1; Chai et al., 2011).  Tau-5 (Invitrogen, Carlsbad, CA) recognizes both human and mouse tau 
and serves as a general marker for tau, independent of pathology.  MC-1 and CP-13 detect 
conformation- and phosphorylation-specific epitopes, respectively, in the earliest stages of AD 
pathology.  PG-5 identifies changes in tau related to mid-stage tau pathology, including 
pretangles (the accumulations of nonargyrophilic hyperphosphorylated tau) in the neuronal cell
 
body.  Lastly, Alz-50 and PHF-1 identify conformational changes in tau and paired helical 
filaments indicative of late-stage tau pathology.  MC-1, CP-13, PG-5, Alz-50, and PHF-1 were 
generous gifts from Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY).  Blots 
were normalized with actin (Santa Cruz Biotechnology, Dallas, TX) to control for variations in 
loading.  To investigate pathological changes in tau, the steps described below were used. 
Dissection and extraction of mouse hippocampus. Two days after the conclusion of 
Barnes maze testing, all mice were euthanized.  Brains were immediately removed and separated 
into the olfactory bulbs, the cerebellum, the prefrontal cortex (PFC), the hippocampi, and the 
remaining forebrain hemispheres, immediately frozen on dry ice, and then stored in the freezer at 
-80 C.  The hippocampi were placed into 200 µl sucrose buffer (10 mM HEPES, 0.32M sucrose 
added the day of use, 40 mM β-glycerophosphoate, 20 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 30 mM NaF, 1 mM EDTA, 1 mM EGTA, 15 µM calpeptin, pH 7.4) with 
protease inhibitors (cOmplete ULTRA  tablets, mini, EDTA-free, Roche diagnostics, Laval, QC, 
Canada) and phosphatase inhibitors (phosSTOP EASYpack, Roche diagnostics, Laval, WC, 
Canada) added fresh the day of extraction.  To homogenize the tissue, the hippocampus was 
passed through a one milliliter (ml) syringe without a needle five times.  The tissue was then 
passed through a syringe with a 20-gauge needle 20 times, and then further dissociated by 
passing it through a 27-gauge needle five times.  The tissue lysate was centrifuged for 10 min at 
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1,000 x g at 4 C, and the resulting supernatant was collected and centrifuged again for 6 min at 
1,000 x g.  Once again, the supernatant was centrifuged at 12,000 x g for 20 min, the resulting 
pellet was discarded, and the supernatant was stored at -80 C.  Protein concentrations in each 
sample were determined by performing a bicinchoninic acid (BCA; Thermo Scientific, 
Rockford, IL) protein assay using bovine serum albumin (BSA; Sigma, St. Louis, MO) as a 
standard.  To adjust the samples so that they had protein concentrations in the BCA linear range, 
the samples were diluted 1:5 with fresh sucrose buffer with added protease and phosphatase 
inhibitors and then frozen at -80°C. 
Western blotting. After the diluted hippocampal tissue samples were thawed, equal 
amounts of protein were aliquoted and mixed with loading buffer (450 mM Tris HCl, pH 8, 8% 
SDS, 24% glycerol, 5% β-mercaptoethanol, 0.1% bromophenol blue, 0.1% phenol red).  Samples 
were then heated to 95 C for 5 min, separated on 8% or 8—16% Tris-HCl sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad, Hercules, CA), and 
transferred onto 0.45 µm polyvinylidene difluoride membranes (Millipore, Bedford, MA).  
Membrane blots were blocked for one hour at room temperature in 5% BSA in 0.1% Tween 
20/Tris-buffered saline (TTBS; 396 mM NaCl, 20 mM Trizma base, pH 7.4).  After blocking, 
membranes were incubated with an antibody directed against the site of interest (Table 1) in 5% 
BSA in TTBS either for one hour at room temperature or overnight at 4C.  After washing the 
membranes with TTBS four times for 5 min each, they were incubated with an HRP-coupled 
secondary antibody (GE Healthcare, Buckinghampshire, UK) in TTBS for 2 hours at room 
temperature. All blots contained a consistent loading control and were stripped with Restore 
Western Blotting Stripping Buffer (Thermo Scientific, Rockford, IL) and re-probed with actin 
(Santa Cruz Biotechnology, Dallas, TX) to ensure equal loading of samples within and across 
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blots. Actin blots were incubated with an AP-coupled secondary antibody (Santa Cruz 
Biotechnology, Dallas, TX) and immunofluoresced with Lumi-Phos (Thermo Scientific, 
Rockford, IL).   
Immunoreactive bands were visualized by enhanced chemiluminescence with either 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) for HRP-
conjugated secondaries or Lumi-Phos (Thermo Scientific, Rockford, IL) for AP-conjugated 
secondaries. Band density was measured using a FluorChem E Imager (Protein Simple, Santa 
Clara, CA). All blots were quantified using Alphaview (Protein Simple, Santa Clara, CA).  Using 
various exposure lengths, the loading control band on different blots of the same antibody was 
matched within 10% across blots.  Both tau and actin bands were quantified as the average pixel 
values in the region.  To account for unequal loading during western blotting, the pixel values of 
the tau bands were divided by the pixel values of the actin bands of the same samples. 
Statistical Analyses 
 Assumptions regarding normality, homogeneity of variance, and independence of errors 
were assessed and met.  Variables of interest during the acquisition trials of the Barnes maze test 
(i.e., hole deviation, primary errors, primary latencies, total errors, and total latencies) were 
evaluated using two-way repeated-measures analyses of variance (RMANOVAs) with the day as 
a within-subjects factor and transgene (Tg: Control, TauWT, or TauP301L) and treatment 
condition (Tx: ICV-vehicle or ICV-STZ) as between-subjects factors.  Variables of interest 
during the probe trials of the Barnes maze (i.e., time spent to reach the target hole, the number of 
encounters with the target hole per bin, and the number of encounters with each error hole per 
bin) were examined using two-way analyses of variance (ANOVAs) with Tg and Tx condition as 
the between-subjects factors.  Search strategy was assessed using chi-square tests.  
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Immunoblotting was also analyzed with two-way ANOVAs with Tg and Tx conditions as 
between-subjects factors.  Bonferroni post-hoc tests followed all significant analyses.  For all 
tests, statistical significance was defined as α=.05.  Reported statistics are the mean ± standard 
error of the mean (SEM). 
Results 
Physiological Parameters 
 Figure 2A shows fasting blood glucose levels taken on the day between the conclusion of 
behavioral testing and euthanasia. There were no differences among treatment (Tx) and 
transgene (Tg) groups [Tx: F(1,33)=1.07, p=.31; Tg: F(2,33)=1.669, p=.20; Tx*Tg: 
F(2,33)=.29, p=.75].  At the time of euthanasia, neither body weights (Figure 2B) nor brain 
weights (Figure 2C) differed among the groups [body weight: Tx: F(1,50)=.06, p=.80; Tg: 
F(2,50)=1.01, p=.37; Tx*Tg: F(2,50)=1.88, p=.16 and brain weight: Tx: F(1,46)=.51, p=.48; 
Tg: F(2,46)=1.74, p=.19; Tx*Tg: F(2,46)=1.18, p=.32]. 
Behavioral Testing 
Acquisition.  For hole deviation, the distance of the first hole visited relative to the target 
hole, there were no statistically significant improvements across days [Figure 3; Table 2].  For 
primary errors (Figure 4A), fewer error hole visits were made as the days progressed [Day: 
F(4,200)=12.16, p<.001].  Figure 4B demonstrates the Day*Tg interaction [F(8,200)=2.77, 
p<.01]; TauWT mice made significantly more primary errors than the Control mice on Day 1, 
but did not differ on any other days.  With the exception of the Day*Tg interaction, the number 
of primary errors did not differ among Tx or Tg groups (Table 2). Primary latency, the time to 
initially locate the target hole, decreased with additional training [Figure 5; Day: 
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F(4,200)=80.91, p<.01].  However, neither Tx nor Tg significantly impacted the time required 
for the mice to first locate the target hole (Table 2). 
Total errors decreased as training progressed [Figure 6; Day: F(4,200)=8.34, p=<.001].  
In addition, there was a Day*Tx*Tg interaction [F(8,200)=1.98, p=.05].  The Vehicle-TauP301L 
mice did not differ from any other groups until Day 5, at which point the Vehicle-TauP301L 
mice made significantly more errors than both the STZ-Control and Vehicle-TauWT mice.  
Neither the effect of Tg and Tx group alone, nor the two-way interactions with Day, were 
statistically different for total errors (Table 2).  For total latency, the mice entered the escape box 
more quickly with each subsequent day of acquisition [Figure 7A; Day: F(4,200)=8.34, p<.001].  
As shown in Figure 7B, a main effect of Tg was observed [Tg: F(2,50)=3.88, p=.027]; 
TauP301L mice, regardless of ICV-STZ treatment or Day, took longer to enter the escape box 
than the Control mice (p=.03), but not the TauWT mice (p=.16).  There were no significant 
differences for total latency between Tx groups or interactions (Table 2).  
Search strategy for Tg, Tx, and Tg-Tx groups was evaluated using chi-squared tests for 
each of the three strategies on Days 1 to 5 of acquisition (Table 3).  On Day 1, there was a 
significant Tx effect for which the use of a serial strategy was significantly higher in vehicle-
treated mice than STZ-treated mice [Figure 8A; χ(3)=9.05, p=.03] and also a significant Tx*Tg 
effect such that Vehicle-TauWT mice used a serial search strategy more than  STZ-Control mice 
[Figure 8B; χ(15)=25.84, p=.04].  
Probe.  For Probe 1 (Table 4), there were no significant Tx*Tg effects for total errors 
(Figure 9A), the 31-60 s bin (Figure 9C), or the 61-90 s bin (Figure 9D), but there was a Tx*Tg 
effect for 0-30 s bin [Figure 9B; F(2,50)=3.34, p=.04].  Post-hoc analyses indicated that, 
although Control and TauWT mice in the ICV-STZ condition did not differ significantly from 
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their respective transgene groups in the vehicle condition, TauP301L mice in the ICV-STZ 
condition made more errors than the TauP301L mice in the vehicle condition in the first time bin 
(p=.04).  In addition, there was a main effect of Tx (Figure 10) for total errors [F(1,50)=5.49, 
p=.02], 0-30 s [F(1,50)=4.39, p=.04], 31-60 s [F(1,50)=3.89, p=.05], and 61-90 s [F(1,50)=5.49, 
p=.02].  There was no Tg effect for any of these bins (Table 4). For escape latency in Probe 1, 
there were no significant differences (Table 4) among Tg or Tx groups (Figure 11).  Escape hole 
visits (Figure 12) also did not significantly differ among groups (Table 2) during the total bin 
(Figure 12A), 0-30 s bin (Figure 12B), 31-60 s bin (Figure 12B), or 61-90 s bin (Figure 12D). 
For Probe 2 error hole visits, there were no Tx*Tg interactions for total errors (Table 4) 
in the total bin (Figure 13A), the 0-30 s bin (Figure 13B), the 31-60 s bin (Figure 13C), or the 
61-90 s bin (Figure 13 D).  There was, however, a significant effect of Tx for errors in the 0-30 s 
bin [Figure 14; F(1,50)=4.08, p=.05], but not any of the other bins (Table 2).  Escape latency in 
Probe 2 did not differ among treatment or transgene groups [Figure 15; Table 4).  Escape hole 
visits (Figure 16) also did not differ among treatment or transgene groups (Table 4). 
Western Blotting 
Tau-5, an antibody that detects both mouse and human tau, indicated that total tau levels 
in TauWT (p<.001) and TauP301L (p=.002) mice were higher than Controls [Figure 17; Tg: 
F(2,34)=11.20, p<.001]. As previously reported (Hoover et al., 2010), TauWT express wild-type 
human tau at concentrations equivalent to P301L human tau in rTgP301L mice. ICV-STZ did 
not alter tau levels as there were no observed differences between Tx groups [F(1,34)=.21, 
p=.65], and there was also no interaction between Tx and Tg [F(2,34)=2.82, p=.07].  
Levels of MC-1, specific for a conformational change in tau associated with early-stage 
AD pathology, were significantly increased in TauP301L mice [Figure 18; Tg: F(1,35)=3.65, 
STREPTOZOTOCIN-INDUCED MODEL OF ALZHEIMER’S DISEASE 31 
 
p=.04] compared to Controls (p=.03), but not TauWT mice (p=0.41).  There was neither a 
significant main effect of Tx [F(1,35)= 0.00, p=.99] nor an interaction between Tx and Tg 
[F(2,35)=.19, p=.83]. Use of CP-13 (Figure 19), an antibody that detects a phosphorylated serine 
indicative of early-stage AD pathology, showed significantly different levels among the groups 
[F(2,34)=13.82, p<.001].  TauWT mice exhibited significantly higher CP-13 levels than both 
Controls (p<.001) and TauP301L (p=.01), but the Control and TauP301L mice did not differ.  
There was no main effect of Tx [F(1,34)=1.13, p=.30] or an interaction between Tx and Tg 
[F(2,34)=.26, p=.78]. 
There was no positive staining in any of the groups when probed using PG-5 or Alz-50 
antibodies. Positive staining with actin confirms the lack of PG-5 and Alz-50 signal was not due 
to inaccurate loading.  
Finally, PHF-1, an antibody that detects paired helical filaments, showed a significant 
main effect of Tg [Figure 20; F(2,21)=4.18, p=.03] such that the TauP301L mice exhibited 
significantly higher levels of paired helical filaments than the Control mice (p=.03), but not the 
TauWT (p=1.00)  mice.  No effect of Tx [F(1,21)=.21, p=.65] or interaction between Tx and Tg 
[F(2,21)=.15, p=.87] was found. 
Discussion 
 Although ICV-STZ has been used extensively to emulate metabolic changes found in the 
AD brain, the findings of the current study provide inconsistent support for the use of an ICV-
STZ model in mice with wild-type human tau.  For many variables of interest for the Barnes 
maze and western blotting, ICV-STZ did not result in an apparent induction or exacerbation of 
pathology in the TauWT or TauP301L groups, respectively.  It is unclear if the lack of ICV-STZ 
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effect in the present study is due to an absence of pathology, perhaps due to a methodological 
divergence from other ICV-STZ studies, or a lack of sensitive measures to detect subtle deficits.   
 Results of the Barnes maze did not indicate that there was a learning or memory deficit in 
the Vehicle-TauP301L mice after approximately three months of tau expression.  The total time 
allowed for the expression of tau plays a key role in the presence and severity of pathology.  It 
may be possible that the assessed time-point was too early for the existence of detectable 
learning and memory deficits.  After two months of tau expression, TauP301L mice have been 
shown to exhibit increases in long-term potentiation in the dentate gyrus and improvements in 
spatial learning and memory accompanied by lower levels of tau phosphorylation than wild-
types at sites detected by AT8, AT180, and AD2 (Boekhoorn et al., 2006).  This finding suggests 
that it is not solely the presence of P301L tau that causes deficits in TauP301L mice; rather, the 
time-dependent alterations in P301L tau such as tau cleavage (Rizzu et al., 2000), 
hyperphosphorylation (Hoover et al., 2010; Ramsden et al., 2005; Terwel et al., 2005), and 
mislocalization (Hoover et al., 2010; Kuchibhotla et al., 2014), that produce synaptic dysfunction 
and cognitive decline.  The mice in the present study represented a time-point at which early 
pathology was expected, but it is possible that it was too premature and that deficits were not yet 
present. 
ICV-STZ also did not produce an obvious induction or exacerbation of behavioral 
deficits.  The period of time between surgery and subsequent behavioral testing and brain 
analyses in the present study was long compared to other published reports.  In most cases, the 
time between STZ-treatment and biochemical and behavioral assays is fewer than six weeks 
(Blokland & Jolles, 1993; Chen et al., 2013; de la Monte et al., 2006, Deng et al., 2009; Hoyer & 
Lannert, 2008; Lester-Coll et al., 2006, Planel et al., 2007).  The current study, in contrast, 
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assessed behavioral deficits at three months post-surgery, and biochemical pathology 3.5 months 
post-surgery.  In one study of non-transgenic rats that received ICV-STZ, there were memory 
deficits as measured by the MWM as far as two months post-surgery (Grünblatt et al., 2007).  In 
a study that encompassed the same time range between ICV-STZ and behavioral and 
biochemical assays as the present study, it was noted that levels of active GSK3β, a kinase that 
phosphorylates tau, in the hippocampus were significantly higher in ICV-STZ rats one month 
post-surgery, but declined to control levels at three months post-surgery (Salkovic-Petrisic et al., 
2006).  The same study, however, found memory deficits at both of the time-points as indicated 
by the MWM (Salkovic-Petrisic et al., 2006).  In one of the longest timeframes, nine-month-old 
transgenic mice with a mutation in the Aβ precursor protein showed deficits in the MWM 6 
months after ICV-STZ (Plaschke et al., 2010).  Because the ICV-STZ studies with longer 
timeframes used either non-transgenic rats or mice with Aβ mutations, it is unclear if there may 
be partial or complete recovery of deficits from the effects of ICV-STZ in mice with human tau.  
Future studies should investigate a potential resistance in human tau to long-term alterations 
induced by ICV-STZ. 
 Although it is possible that there were no learning and memory deficits induced by ICV-
STZ in the present study, one additional concern involves the possible inability of the Barnes 
maze to have detected subtle deficits if present.  The definition of search strategy, in particular, 
may need to be revised to truly encompass a spatial search strategy.  The definition of a serial 
search strategy in the present study indicated that the first hole visited must be within two holes 
of the target hole, and the mouse cannot visit a hole further than two holes from the target hole.  
Because the Barnes maze used has 40 holes, this definition may be too restrictive.  In a 12-hole 
Barnes maze with mice, a serial search strategy was indicated by the mouse first visiting the 
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target hole or the hole on either side, thus making 25% of the holes correspond to a serial search 
strategy (Harrison et al., 2006).  In a 20-hole Barnes maze, the same definition of a spatial search 
strategy encompassing either adjacent hole was used, corresponding to a total of 15% of the 
holes on the platform (Sunyer, Patil, Höger, & Lubec, 2007).  In the 40-hole Barnes maze used in 
the current study, only 12.5% of holes correspond to a spatial search strategy.  This strict 
definition may have resulted in coding some trials as serial or random even when a spatial search 
strategy was being used.  The persistent use of a serial search strategy is often an indication of a 
spatial memory deficit (Harrison et al., 2006), and by coding a large number of trials as serial 
due to strict requirements for a spatial search strategy, differences between truly impaired and 
unimpaired mice are potentially minimized.  Although amending the search strategy definitions 
may improve the accuracy of future behavioral testing, in the present study, however, recoding 
the search strategy for each trial was not warranted given the overall lack of significant main 
effects. 
An unexpected finding came from the significantly higher levels of CP-13 
immunoreactivity in the TauWT mice compared to the TauP301L mice, regardless of STZ 
exposure.  The low levels of tau phosphorylation at Ser202 detected by CP-13, coupled with the 
lack of consistent behavioral deficits, may again be explained by the facilitated learning and 
memory reported in young TauP301L mice prior to the onset of severe pathology (Boekhoorn et 
al., 2006).   
Positive staining was not observed for PG-5 or Alz-50.  Neither PG-5 nor Alz-50 have 
been used in any studies evaluating the effects of STZ treatment.  The epitope recognized by PG-
5, pSer409, is phosphorylated in a pKa-dependent manner (Jicha et al., 1999).  Although it is 
known that ICV-STZ acts through pathways involving GSK3β, PI3K-Akt (Ponce-Lopez, Liy-
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Salmeron, Hong, & Meneses, 2011), and Akt/GSK-3/PP-2A (Qu et al., 2011), it is unknown if a 
pKa-dependent pathway capable of phosphorylating Ser409 is similarly induced by ICV-STZ.  
Furthermore, lack of PG-5 immunoreactivity has previously been observed in TauP301L and 
related mutations (Dutschmann et al., 2010; Vanhelmont et al., 2010) suggesting that the 
particular mutation present in these models may not induce phosphorylation at Ser409.  In 
TauP301L and Tau-R406W (another FTDP-17 model of AD) mutations expressed in yeast, 
levels of PG-5 epitopes are drastically reduced and almost absent, respectively, compared to 
epitopes defined by other antibodies specific for pathological tau changes including AT8, 
AT180, and AT270 (Vanhelmont et al., 2010). It is also possible that the timeframe of the 
current study played a prominent role in the lack of PG-5 staining.  PG-5 epitopes have been 
characterized as absent or occasional until after four to 5.5 months of tau expression (Ramsden et 
al., 2005).  If the timeframe of the present study had continued beyond 3.5 months of tau 
expression, it is possible that PG-5 epitopes could have been detected. 
Even though the conformational change recognized by Alz-50 has been previously 
detected after 2.5 months of tau expression in TauP301L mice (Ramsden et al., 2005) and even 
after only three weeks in 3xTg-AD mice, which have a TauP301L mutation and mutations in Aβ 
(Oh et al., 2010), no Alz-50 staining was found in the present study.  Because there is no 
literature on effects of ICV-STZ on Alz-50 immunoreactivity, it is unclear what effect STZ may 
have on the amino acids involved in the conformation-specific change.  In the present study, the 
dilution of Alz-50 was 1:50, which has been shown to be strong enough to detect a prominent 
signal (Ramsden et al., 2005; Uéda et al., 1990).  However, dilutions as high as 1:10 have also 
been successfully used (Vincent & Davies, 1990), and may have been capable of detecting a 
weaker signal, if present at all. 
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Even though there was no positive staining with PG-5 and Alz-50, there was detectable 
immunoreactivity with PHF-1.  It was not anticipated that late-stage markers of AD pathology 
would be detected in the absence of the mid-stage markers; however, paired helical filaments 
detected by PHF-1 have previously been found in high levels in STZ-treated rodents (Grünblatt 
et al., 2007; Planel et al., 2007; Qu et al., 2011).  At three months post ICV-STZ in three- to 
four-month old male Wistar rats, levels of phosphorylated tau visualized through the use of PHF-
1 were significantly increased over vehicle-treated controls (Grünblatt et al., 2007).  In non-
transgenic mice injected peripherally with STZ, there was also a mild increase at 10 days post-
infusion in the phosphorylation of Ser396 and Ser404, the sites recognized by PHF-1.  This 
significant increase continued to rise substantially through the final 40-day time-point (Planel et 
al., 2007).  The present study assessed pSer396
 
and pSer404 after approximately 3.5 months of 
tau expression, and it is possible that the phosphorylation of PHF-1 epitopes similarly increased 
with time. 
 It is still plausible that ICV-STZ treatment can be used to induce cerebral glucose 
metabolism deficiencies in mice with human wild-type tau, but additional studies should use 
alternative and multiple behavioral assays to detect subtle differences among groups.  It may also 
be necessary to train the mice for additional acquisition trials to improve the performance of the 
Controls and thus increase the dynamic range.  Future studies should also investigate effects of 
ICV-STZ on human tau at different time periods post-surgery, and also at older ages at which 
more severe pathology would be expected. 
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Antibody Species Specificity Use Dilution 
Tau-5 Mouse Tau; human/mouse 
specific 
Tau marker 1:1,000 
MC-1 Mouse Tau; conformational 
epitope, 7-9 and 326-
330 aa 
Conformation specific; early 
pathological change in AD 
1:50 
CP-13 Mouse Tau; pSer202 Phosphorylation specific; early 
pathological change in AD 
1:50 
PG-5 Mouse Tau; pSer409 Pre-tangles; mid-stage 1:50 
Alz-50 Mouse Tau; conformational 
epitope, 3-15 and 312-
322 aa
 
Conformation specific; late-
stage 
1:50 
PHF-1 Mouse Tau; pSer396/pSer404 Paired helical filaments of tau; 
late-stage 
1:50 
Actin Goat C-terminus Loading control 1:500 
Anti-mouse Sheep  HRP-conjugated secondary 1:5,000 
Anti-goat Donkey  AP-conjugated secondary 1:5,000 
 
Table 1. Antibodies used to assess tau pathology.  Several antibodies capable of recognizing 
distinct characteristics of tau pathology progression were used. 
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Table 2. Statistical results for acquisition. There were no significant effects of Tx, Tx*Tg, or 
Day*Tx on any variable, and with the exception of total latency (*p≤.05), there were also no 
main effects of Tg.  For primary errors (***p<.001), primary latency (***p<.001), total errors 
(***p<.001), and total latency (***p<.001), there was a significant effect of Day.  For primary 
errors, there was a significant interaction between Day and Tg (**p<.01).  Lastly, for total errors, 
there was a significant Day*Tx*Tg interaction (*p≤.05). 
  
Hole Deviation Primary Errors Primary Latency Total Errors Total Latency
Tx
F (1,50)=1.52, 
p =.22
F (1,50)=0.22, 
p =.64
F (1,50)=1.13, 
p =.29
F (1,50)=1.81, 
p =.19
F (1,50)=0.21,      
p =.65
Tg
F (2,50)=0.74, 
p =.48
F (2,50)=1.22, 
p =.30
F (2,50)=1.24, 
p =.30
F (2,50)=1.80, 
p =.18
F (2,50)=3.88, 
p =.03*
Tx*Tg
F (2,50)=0.25, 
p =.78
F (2,50)=0.58, 
p =.56
F (2,50)=1.50, 
p =.23
F (2,50)=1.00, 
p =.37
F (2,50)=0.39, 
p =.68
Day
F (4,200)=2.02, 
p =.09
F (4,200)=12.16, 
p <.001***
F (4,200)=80.91, 
p <.001***
F (4,200)=8.34, 
p <.001***
F (4,200)=53.01, 
p <.001***
Day*Tx
F (4,200)=1.52, 
p =.20
F (4,200)=1.68, 
p =.16
F (4,200)=2.17, 
p =.07
F (4,200)=1.49, 
p =.21
F (4,200)=1.50, 
p =.21
Day*Tg
F (8,200)=0.69, 
p =.70
F (8,200)=2.771, 
p< .01**
F (8,200)=0.16, 
p =.99
F (8,200)=0.65, 
p =.74
F (8,200)=0.50, 
p =.86
Day*Tx*Tg
F (8,200)=0.54, 
p =.83
F (8,200)=1.01, 
p =.43
F (8,200)=0.58 
p =.79
F (8,200)=1.98, 
p =.05*
F (8,200)=0.77, 
p =.63
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Table 3. Search strategy. On Day 1, there was a significant effect of Tx for the use of a serial 
search strategy in that a serial approach was utilized more often by mice in the vehicle-treated 
group than the STZ-treated group (*p=.03). There was also a TxTg effect for serial search 
strategy on Day 1 such that the Vehicle-TauWT mice the serial search strategy significantly 
more often than the STZ-Control mice (#p=.04). 
 
 
  
Random Serial Spatial Random Serial Spatial
Tg
X (3)=2.2, 
p =.54
X (3)=1.84, 
p =.61
X (2)=3.48, 
p =.18
X (3)=2.39, 
p =.50
X (3)=3.90, 
p =.27
X (1)=0.83, 
p =0.64
Tx
X (3)=7.0, 
p =.07
X (3)=9.05, 
p =.03*
X (2)=1.02, 
p =.60
X (3)=1.57, 
p =.67
X (3)=1.11, 
p =.77
X (1)=0.33, 
p =.57
TgTx
X (15)=19.30, 
p =.20
X (15)=25.84, 
p =.04
#
X (10)=8.18, 
p =.61
X (15)=14.84, 
p =.46
X (15)=13.05, 
p =.60
X (5)=4.77, 
p =.45
Random Serial Spatial Random Serial Spatial
Tg
X (3)=2.05, 
p =.56
X (3)=2.30, 
p =.51
X (2)=0.52, 
p =.77
X (2)=3.18, 
p =.20
X (3)=3.24, 
p =.36
X (2)=1.28, 
p =.53
Tx
X (3)=2.02, 
p =.57
X (3)=1.24, 
p =.74
X (2)=1.13, 
p =.57
X (2)=0.92, 
p =.63
X (3)=1.46, 
p =.69
X (2)=2.02, 
p =.37
TxTg
X (15)=16.35, 
p =.36
X (15)=13.78, 
p =.54
X (10)=9.68, 
p =.47
X (10)=6.57, 
p =.77
X (15)=9.54, 
p =.85
X (10)=9.33, 
p =.50
Random Serial Spatial
Tg
X (2)=3.18, 
p =.20
X (3)=4.35, 
p =.28
X (2)=1.28, 
p =.53
Tx
X (2)=1.13, 
p =.57
X (3)=4.37, 
p =.22
X (2)=4.28, 
p =.12
TxTg
X (10)=10.75, 
p =.38
X (15)=24.42, 
p =.06
X (10)=15.42, 
p =.12
Day 5
Day 1 Day 2
Day 3 Day 4
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Table 4. Statistical results for Probe 1 and Probe 2.  Although there were no significant Tg 
effects, for all bins of Probe 1 and the 0-30 s bin of Probe 2, there were significant effects of Tx 
(*p≤.05).  There was also a significant interaction between Tx and Tg in the 0-30 s bin of Probe 
1 (*p≤.05). 
  
Tx Tg Tx*Tg
Escape Latency F (1,50)=0.20, p =.66 F (2,50)=0.51, p =.61 F (2,50)=1.38, p =.26
Escape Holes 0-30s F (1,50)=0.79, p =.38 F (2,50)=0.20, p =.82 F (2,50)=1.12, p =.34
Escape Holes 31-60s F (1,50)=0.38, p =.54 F (2,50)=0.05, p =.96 F (2,50)=0.44, p =.65
Escape Holes 61-90s F (1,50)=0.00, p =.98 F (2,50)=1.70, p =.19 F (2,50)=1.79, p =.18
Escape Holes Total F (1,50)=0.06, p =.81 F (2,50)=0.29, p =.75 F (2,50)=1.25, p =.29
Error Holes 0-30s F (1,50)=4.39, p =.04* F (2,50)=0.33, p =.72 F (2,50)=3.34, p =.04*
Error Holes 31-60s F (1,50)=3.89, p =.05* F (2,50)=2.69, p= .08 F (2,50)=0.31, p =.73
Error Holes 61-90s F (1,50)=7.09, p =.01* F (2,50)=2.06, p =.14 F (2,50)=0.23, p =.79
Error Holes Total F (1,50)=5.49, p =.02* F (2,50)=2.90, p =.06 F (2,50)=0.70, p =.50
Escape Latency F (1,50)=0.61, p =.44 F (2,50)=0.64, p =.89 F (2,50)=1.22, p =.30
Escape Holes 0-30s F (1,50)=0.20, p =.66 F (2,50)=1.54, p =.23 F (2,50)=0.29, p =.75
Escape Holes 31-60s F (1,50)=2.05, p =.16 F (2,50)=0.09, p =.91 F (2,50)=0.73, p =.49
Escape Holes 61-90s F( 1,50)=0.24, p =.63 F (2,50)=1.06, p =.36 F (2,50)=0.48, p =.62
Escape Holes Total F (1,50)=0.61, p =.44 F =(2,50)=0.15, p =.86 F(2,50)=0.39, p =.68
Error Holes 0-30s F (1,50)=4.08, p =.05* F (2,50)=1.28, p =.51 F(2,50)=0.56, p =.57
Error Holes 31-60s F (1,50)=0.68, p =.42 F (2,50)=0.12, p =.89 F(2,50)=0.09, p =.92
Error Holes 61-90s F (1,50)=1.81, p =.19 F (2,50)=0.02, p =.98 F(2,50)=0.58, p =.57
Error Holes Total F (1,50)=2.31, p =.13 F (2,50)=0.12, p =.88 F(2,50)=0.17, p =.85
Probe 1
Probe 2
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Figure 1. Mouse models and timeline.  (A) There was a total of 56 male mice in the experiment, 
with nine to eleven mice in each group. (B) Both TauWT and TauP301L responder lines encode 
for human 4R tau lacking the amino terminal sequences (4R0N).  The activator line used a 
forebrain specific promoter (CaMKIIα) to restrict tau expression to AD relevant brain regions. 
The addition of doxycycline (40 ppm) to the drinking water prevents the transcription of tau by 
preferentially binding to the tetracycline transactivator protein. When doxycycline is removed, 
transcription occurs. (C) Tau expression was suppressed during development using doxycycline 
and turned on from two to five months of age. ICV-STZ or ICV-vehicle surgery was performed 
at two months of age, and at the same time, tau expression began. 
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Figure 2. Physiological parameters.  (A) Body weight, (B) blood glucose levels, and (C) brain 
weights did not differ among treatment or transgene groups. 
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Figure 3. Hole deviation.  Unlike the other acquisition variables, there was no significant trend 
of improvement for hole deviation across days. 
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Figure 4.  Primary errors. (A) Fewer visits to error holes were made as the acquisition days 
progressed.  (B) On Day 1 of acquisition, there was a Day*Tg interaction in which the TauWT 
mice made significantly more errors than the Control mice (TauWT vs. Control: *p=.04), but did 
not differ on any other days (p>.05). 
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Figure 5.  Primary latency.  The time required for the mice to initially locate the target hole 
decreased with subsequent acquisition days. 
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Figure 6. Total errors.  The Vehicle-TauP301L mice made more errors than either the STZ-
Control (Vehicle-TauP301L vs. STZ-Control: *p=.01) or Vehicle-TauWT (Vehicle-TauP301L 
vs. STZ-Control: #p=.02) on Day 5. 
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Figure 7.  Total latency.  (A) All of the groups made improvements in finding the escape box 
across days.  (B) For total latency, there was a Tg effect such that the TauP301L mice 
consistently required more time to get into the escape box than the Control mice (*p=.03) but not 
the TauWT mice (p=.16).  
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Figure 8. Search strategy on day 1of acquisition.  (A) The vehicle-treated mice were 
significantly more likely to use a random search strategy and less likely to use a serial strategy 
than the vehicle-treated mice (Vehicle vs. STZ: *p=.03).  (B) There was also a Tx*Tg interaction 
for the use of a serial search strategy (Vehicle-TauWT vs. STZ-Control: #p=.04), in which the 
Vehicle-TauWT mice were more likely to use a serial search strategy than the STZ-Control 
mice.     
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Figure 9.  Probe 1 error hole visits. (A) Although there was no Tx*Tg interaction in the total bin,  
(B) there was a Tx*Tg interaction for the 0-30 s bin such that the STZ-TauP301L mice made the 
most errors of all groups, but the Vehicle-TauP301L mice made fewest errors (Tx*Tg: *p<.05).  
There was no Tx*Tg interaction for either (C) the 31-60 s or 61-90 s bin.  
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Figure 10.  Tx effect for Probe 1 error hole visits.  There was a significant Tx effect in each of 
the bins such that STZ-treated mice made more errors than vehicle-treated mice (*p≤.05): total 
(p=.02), 0-30 s (p=.05), 31-60 s (p=.05), and 61-90 s (p=.01).   
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Figure 11.  Probe 1 escape latency.  There were no significant differences between treatment or 
transgene groups in the time taken for mice to initially locate the escape hole where the escape 
box was formerly located in Probe 1.   
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Figure 12.  Probe 1 escape hole visits.  There were no differences among Tx and Tg in the 
number of visits to the escape holes during any of the bins of Probe 1. 
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Figure 13. Probe 2 error hole visits.  (A) There was not a significant interaction between Tx and 
Tg for error hole visits in the (A) total, (B) 0-30 s, (C) 31-60 s, or (D) 61-90 s bins. 
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Figure 14.  Tx effect for Probe 2 error hole visits.  For the 0-30 s bin, the STZ-treated mice 
visited significantly more error holes (*p=.05). In the remaining time bins, there were no 
differences between Tx groups. 
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Figure 15.  Probe 2 escape latency.  There were no significant differences among treatment or 
transgene groups in the time taken for mice to initially locate the escape hole where the escape 
box was formerly located in Probe 2. 
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Figure 16.  Probe 2 escape hole visits.  There were no significant differences among Tx or Tg 
groups in the (A) total number of visits to the escape holes or during the (B) 0-30 s, (C) 31-60 s, 
or (D) 61-90 s bins. 
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Figure 17. Western blotting with Tau-5.  (A) The TauWT and TauP301L both had dark bands of 
total tau detected by Tau-5 and normalized with actin. (B) Levels of total tau are lower in the 
Control mice; in fact, (C) a main effect of Tg indicates that the TauWT and TauP301L mice had 
significantly higher total tau levels (*p<.05) than the Control mice, but did not differ from each 
other.  
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Figure 18.  Western blotting with MC-1.  (A) Bands of an early-stage conformational change 
detected by MC-1 were less profound than the bands of Tau-5 (n=40).  (B) TauP301L mice had 
the highest level of MC-1—detected pathology normalized by actin, and (C) a main effect of Tg 
demonstrates that the TauP301L mice had significantly higher levels than the Control mice 
(*p<.05) but not the TauWT mice. 
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Figure 19. Western blotting with CP-13.  (A) Faint bands of phosphorylated serine at the 202
nd
 
(pSer202) position, an early-stage change in AD, were detected by CP-13 (n=40).  (B) The 
TauWT mice had higher levels of CP-13—detected changes normalized with actin.  (C)  A main 
effect of Tg shows that the TauWT mice had significantly more pSer
202
 than the Control and 
TauP301L mice (*p<.01).  
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Figure 20. Western blotting with PHF-1.  (A) PHF-1 identified paired helical filaments (n=27).  
(B) Levels of paired helical filaments normalized with actin were low in Control mice and higher 
in the TauWT and TauP301L mice.  (C) The main effect of Tg was significant, indicating that 
the TauP301L mice had higher levels of paired helical filaments than the Control mice (*p<.05), 
but not the TauWT mice. 
